Literature DB >> 7150460

Cimetidine, but not oxmetidine, penetrates into the cerebrospinal fluid after a single intravenous dose.

K A Jönsson, S E Eriksson, I Kagevi, B Norlander, G Bodemar, A Walan.   

Abstract

1 Thirty-six patients with various neurological diseases or symptoms received single intravenous doses of either cimetidine 400 mg (n = 19) or oxmetidine 200 mg (n = 17), 15 or 60 min before a diagnostic lumbar puncture. 2 In the 15 min CSF samples concentrations of cimetidine were detectable but not measurable in 5 and non-detectable in 3 patients. 3 In the 60 min CSF samples the concentrations of cimetidine were detectable in all 11 patients and were measurable in 8 of these patients with a mean +/- s.e. mean of 0.12 +/- 0.01 microgram/ml. These CSF concentrations were correlated to simultaneously measured plasma concentrations (P less than 0.01). The mean ratio CSF/plasma concentration was 0.03. 4 No detectable concentrations of oxmetidine were found either in the 15 min (n = 9) or in the 60 min (n = 8) liquor samples. 5 Cimetidine penetrates the blood-drain barrier slowly and not freely after a single dose. Our data suggest that the new histamine H2-receptor antagonist oxmetidine does not cross this barrier.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7150460      PMCID: PMC1427541          DOI: 10.1111/j.1365-2125.1982.tb02042.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  High-pressure liquid chromatographic analysis of cimetidine, a histamine H2-receptor antagonist, in blood and urine.

Authors:  W C Randolph; V L Osborne; S S Walkenstein; A P Intoccia
Journal:  J Pharm Sci       Date:  1977-08       Impact factor: 3.534

2.  Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values.

Authors:  G Tibbling; H Link; S Ohman
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

3.  The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine--studies in patients with peptic ulcer disease.

Authors:  G Bodemar; B Norlander; L Fransson; A Walan
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

4.  High-pressure liquid chromatographic determination of cimetidine sulphoxide in human blood and urine.

Authors:  R M Lee; P M Osborne
Journal:  J Chromatogr       Date:  1978-09-01

5.  Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis.

Authors:  R Larsson; P Erlanson; G Bodemar; B Norlander; L Fransson; L Strouth
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.

Authors:  R Larsson; P Erlanson; G Bodemar; A Walan; A Bertler; L Fransson; B Norlander
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

7.  Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.

Authors:  J J Schentag; F B Cerra; G Calleri; E DeGlopper; J Q Rose; H Bernhard
Journal:  Lancet       Date:  1979-01-27       Impact factor: 79.321

Review 8.  Cimetidine: adverse reactions and acute toxicity.

Authors:  D Sawyer; C S Conner; R Scalley
Journal:  Am J Hosp Pharm       Date:  1981-02
  8 in total
  11 in total

Review 1.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  CSF concentrations of famotidine.

Authors:  I Kagevi; E Thorhallsson; L Wählby
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

4.  No detectable concentrations of oxmetidine but measurable concentrations of cimetidine in cerebrospinal fluid (CSF) during multiple dose treatment.

Authors:  K A Jönsson; S E Eriksson; I Kagevi; B Norlander; G Bodemar; A Walan
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

5.  Cimetidine elimination from the cerebrospinal fluid of the rat.

Authors:  M T Whittico; K M Giacomini
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

Review 6.  Clinical pharmacokinetics of cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

Review 7.  Behavioural effects of histamine and its antagonists: a review.

Authors:  J M White; G R Rumbold
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 8.  Adverse reactions and interactions with H2-receptor antagonists.

Authors:  J Penston; K G Wormsley
Journal:  Med Toxicol       Date:  1986 May-Jun

Review 9.  Using miniature brain implants in rodents for novel drug discovery.

Authors:  Ben Waldau
Journal:  Expert Opin Drug Discov       Date:  2019-03-04       Impact factor: 7.050

10.  Curcuma longa normalized cimetidine-induced pituitary-testicular dysfunction: Relevance in nutraceutical therapy.

Authors:  Ngozi Joy Onwuemene; Christian Eseigbe Imafidon; Abiodun Oladele Ayoka
Journal:  Animal Model Exp Med       Date:  2019-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.